Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Watchdog Says Report of 10,000 Toddlers on ADHD Drugs Tip of the Iceberg—274,000 0-1 Year Olds and 370,000 Toddlers Prescribed Psychiatric Drugs
  • USA - English


News provided by

Citizens Commission on Human Rights International

May 21, 2014, 09:00 ET

Share this article

Share toX

Share this article

Share toX


Hundreds of thousands of toddlers are being prescribed powerful psychiatric drugs, and more than 274,000 0-1 year olds, that are not mentioned in the new CDC report, are also being drugged.

Post this

Los Angeles, California (PRWEB) May 21, 2014 -- While the recent New York Times article, “Thousands of Toddlers Are Medicated for A.D.H.D., Report Finds, Raising Worries,” seems shocking, the actual numbers of infants and toddlers being prescribed psychiatric drugs dwarfs the 10,000 2-3 year olds being prescribed ADHD drugs.[1] The mental health watchdog, Citizens Commission on Human Rights (CCHR) says according to data provided by IMS Health, the world’s leading health information and analytics company, hundreds of thousands of toddlers are being prescribed far more powerful psychiatric drugs than just ADHD drugs, and most alarming of all is the more than 274,000 0-1 year olds prescribed psychiatric drugs.[2]

According to IMS Health’s Vector One: National and Total Patient Tracker Database for 2013 these are the figures for 0-1 year olds being prescribed psychiatric drugs:

• 249,669 0-1 year olds are on anti-anxiety drugs (such as Xanax, Klonopin, and Ativan).
• 26,406 0-1 year olds are on antidepressants (such as Prozac, Zoloft, and Paxil).
• There are 1,422 0-1 year olds taking ADHD drugs (such as Ritalin, Adderall, and Concerta).
• 654 0-1 year olds are taking antipsychotics (such as Risperdal, Seroquel, and Zyprexa).

While the CDC was correct in issuing their report on the 10,000 2-3 year olds (toddlers) being prescribed ADHD drugs, the number of toddlers on anti-anxiety and antidepressants is staggering in comparison:

• 318,997 2-3 year olds are on anti-anxiety drugs.
• 46,102 2-3 year olds are on antidepressants.
• 3,760 2-3 year olds are taking antipsychotics.

And as for other age groups, the numbers start in the millions with 0-5 year olds:

• The total number of 0-5 year olds currently prescribed psychiatric drugs is 1,080,168.
• The number of 6-12 year olds on psychiatric drugs is 4,130,340.
• The number of 13-17 year olds taking psychiatric drugs is 3,617,593.[3]

The above are stunning data and, yet, the most egregious element of the ever-increasing number of America's children being prescribed psychiatric drugs, is that the diagnosis needed in order to have the drugs prescribed, is subjective—there is no medical test to support or validate even one psychiatric diagnosis. As Allen Frances, a psychiatrist and former DSM-IV Task Force Chairman, stated, "There are no objective tests in psychiatry—no X-ray, laboratory or exam finding that says definitively that someone does or does not have a mental disorder. There is no definition of mental disorder. It's bull…. I mean you just can't define it."[4]

According to the Final Statement from the National Institutes of Health Consensus Conference on ADHD, "we do not have an independent, valid test for ADHD, and there are no data to indicate ADHD is due to a brain malfunction."[5]

When it comes to the psychiatric drugs used to treat ADHD, these are referred to as "kiddie cocaine" for a reason. Ritalin (methylphenidate) Adderall (amphetamine) and Concerta, are all considered by the federal government as Schedule II drugs—the most addictive.[6] ADHD drugs also have serious side effects such as agitation, mania, aggressive or hostile behavior, seizures, hallucinations, and even sudden death, according to the National Institutes of Health.[7] And the Food and Drug Administration still mandates that all labels for ADHD stimulants state "Long-term effects of amphetamines in children have not been well established."[8]

As far as antipsychotics, antianxiety drugs and antidepressants, the FDA and international drug regulatory agencies cite side effects including, but not limited to, psychosis, mania, suicidal ideation, heart attack, stroke, diabetes, and even sudden death.[9]

In summary: Yes, the recent report of the CDC on the number of toddlers being prescribed ADHD drugs is shocking, but it is nowhere near the actual figure of infants, toddlers, and children being drugged. Being shocked is a good place to start, but action is required to protect the weakest among us. As John F. Kennedy stated,"Children are the world's most valuable resource and its best hope for the future." It is time to start protecting our children and it starts with informing parents. For more information visit the Parents Know Your Rights page.

--

About Citizens Commission on Human Rights: CCHR is a non-profit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR has helped to enact more than 150 laws protecting individuals from abusive or coercive mental health practices.

[1] Alan Schwarz, "Thousands of Toddlers Are Medicated for A.D.H.D., Report Finds, Raising Worries," The New York Times, May 16, 2014, nytimes.com/2014/05/17/us/among-experts-scrutiny-of-attention-disorder-diagnoses-in-2-and-3-year-olds.html?_r=3

[2] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Year 2013, Data extracted April 2014, for all Psychiatric Drugs and Per Class for Ages 0-17.

[3] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Year 2013, Data extracted April 2014.

[4] Allen Frances, "Psychiatric Fads and Overdiagnosis," Psychology Today, June 2, 2010, psychologytoday.com/blog/dsm5-in-distress/201006/psychiatric-fads-and-overdiagnosis

[5] "Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder," National Institutes of Health Consensus Development Conference Statement, November 16-18, 1998, consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder110html.htm

[6] "'Kiddie Cocaine': Behavior Drug Ritalin Abused by Children," CBS News, January 31, 2002, cbsnews.com/news/kiddie-cocaine-behavior-drug-ritalin-abused-by-children/; "Schedule 2 (II) Drugs," Drugs.com, drugs.com/schedule-2-drugs.html

[7] "Methylphenidate," and “Dextroamphetamine and Amphetamine,” MedlinePlus, National Library of Medicine, National Institutes of Health, nlm.nih.gov/medlineplus/druginfo/meds/a682188.html and nlm.nih.gov/medlineplus/druginfo/meds/a601234.html

[8] “Adderall,” FDA Access Data, accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf

[9] "Fluoxetine," "Quetiapine," and "Risperidone," MedlinePlus, National Library of Medicine, National Institutes of Health, http://www.nlm.nih.gov/medlineplus/druginfo/meds/a689006.html, nlm.nih.gov/medlineplus/druginfo/meds/a698019.html, and nlm.nih.gov/medlineplus/druginfo/meds/a694015.html

Media Department, Citizens Commission on Human Rights International, http://www.cchrint.org, +1 323-467-4242, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.